Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab

Robert I. Griffiths; Deepa Lalla; Robert J. Herbert; Justin F. Doan; Melissa G. Brammer; Mark D. Danese

doi:10.3109/07357907.2011.616251

Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab

Robert I. Griffiths, Deepa Lalla, Robert J. Herbert, Justin F. Doan, Melissa G. Brammer, Mark D. Danese

School of Medicine

Research output: Contribution to journal › Article

Abstract

We used Surveillance, Epidemiology, and End ResultsMedicare data (2000-2006) to describe treatment and survival in women diagnosed with metastatic breast cancer (MBC) who received trastuzumab. There were 610 patients with a mean age of 74 years. Overall, 32% received trastuzumab alone and 47% received trastuzumab plus a taxane. In multivariate analysis, trastuzumab plus chemotherapy was associated with a lower adjusted cancer mortality rate (Hazard Ratio [HRé 0.54; 95% Confidence Interval [CIé 0.39-0.74; p < .001) than trastuzumab alone among patients who received trastuzumab as part of first-line therapy. Adding chemotherapy to first-line trastuzumab for metastatic breast cancer is associated with improved cancer survival.

Original language	English (US)
Pages (from-to)	573-584
Number of pages	12
Journal	Cancer Investigation
Volume	29
Issue number	9
DOIs	https://doi.org/10.3109/07357907.2011.616251
State	Published - Nov 1 2011

Fingerprint

Keywords

Breast cancers
Chemotherapy
Outcomes research

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

Griffiths, R. I., Lalla, D., Herbert, R. J., Doan, J. F., Brammer, M. G., & Danese, M. D. (2011). Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab. Cancer Investigation, 29(9), 573-584. https://doi.org/10.3109/07357907.2011.616251

@article{64b2adfe3c9640f7af4729c5f0bfec77,

title = "Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab",

abstract = "We used Surveillance, Epidemiology, and End ResultsMedicare data (2000-2006) to describe treatment and survival in women diagnosed with metastatic breast cancer (MBC) who received trastuzumab. There were 610 patients with a mean age of 74 years. Overall, 32% received trastuzumab alone and 47% received trastuzumab plus a taxane. In multivariate analysis, trastuzumab plus chemotherapy was associated with a lower adjusted cancer mortality rate (Hazard Ratio [HR{\'e} 0.54; 95% Confidence Interval [CI{\'e} 0.39-0.74; p < .001) than trastuzumab alone among patients who received trastuzumab as part of first-line therapy. Adding chemotherapy to first-line trastuzumab for metastatic breast cancer is associated with improved cancer survival.",

keywords = "Breast cancers, Chemotherapy, Outcomes research",

author = "Griffiths, {Robert I.} and Deepa Lalla and Herbert, {Robert J.} and Doan, {Justin F.} and Brammer, {Melissa G.} and Danese, {Mark D.}",

year = "2011",

month = nov

day = "1",

doi = "10.3109/07357907.2011.616251",

language = "English (US)",

volume = "29",

pages = "573--584",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "9",

}

TY - JOUR

T1 - Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab

AU - Griffiths, Robert I.

AU - Lalla, Deepa

AU - Herbert, Robert J.

AU - Doan, Justin F.

AU - Brammer, Melissa G.

AU - Danese, Mark D.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - We used Surveillance, Epidemiology, and End ResultsMedicare data (2000-2006) to describe treatment and survival in women diagnosed with metastatic breast cancer (MBC) who received trastuzumab. There were 610 patients with a mean age of 74 years. Overall, 32% received trastuzumab alone and 47% received trastuzumab plus a taxane. In multivariate analysis, trastuzumab plus chemotherapy was associated with a lower adjusted cancer mortality rate (Hazard Ratio [HRé 0.54; 95% Confidence Interval [CIé 0.39-0.74; p < .001) than trastuzumab alone among patients who received trastuzumab as part of first-line therapy. Adding chemotherapy to first-line trastuzumab for metastatic breast cancer is associated with improved cancer survival.

AB - We used Surveillance, Epidemiology, and End ResultsMedicare data (2000-2006) to describe treatment and survival in women diagnosed with metastatic breast cancer (MBC) who received trastuzumab. There were 610 patients with a mean age of 74 years. Overall, 32% received trastuzumab alone and 47% received trastuzumab plus a taxane. In multivariate analysis, trastuzumab plus chemotherapy was associated with a lower adjusted cancer mortality rate (Hazard Ratio [HRé 0.54; 95% Confidence Interval [CIé 0.39-0.74; p < .001) than trastuzumab alone among patients who received trastuzumab as part of first-line therapy. Adding chemotherapy to first-line trastuzumab for metastatic breast cancer is associated with improved cancer survival.

KW - Breast cancers

KW - Chemotherapy

KW - Outcomes research

UR - http://www.scopus.com/inward/record.url?scp=80054859025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054859025&partnerID=8YFLogxK

U2 - 10.3109/07357907.2011.616251

DO - 10.3109/07357907.2011.616251

M3 - Article

C2 - 21929325

AN - SCOPUS:80054859025

VL - 29

SP - 573

EP - 584

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 9

ER -

Access to Document

10.3109/07357907.2011.616251